The ICICI Prudential Pharma Healthcare & Diagnostics Fund has delivered a 25.4% annual return over three years, outpacing its benchmark and major peers. This performance highlights the fund's strategy within the healthcare sector, though investors should note that sector-specific funds carry higher concentration risks compared to diversified portfolios.
The ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund has emerged as the leading performer in its category over the three-year period ending July 2026. According to data from ACE MF, the fund recorded a compound annual growth rate (CAGR) of 25.4 percent. This result stands out significantly against its benchmark index, which returned 9.2 percent over the same timeframe, marking an outperformance of 16.2 percentage points.
Comparing Peer Performance and AUM
The fund’s long-term returns have placed it ahead of other prominent names in the sector. Over the same three-year period, the SBI Healthcare Opp Fund and the Mirae Asset Healthcare Fund recorded returns of 24.3 percent and 23.3 percent, respectively. To ensure a meaningful comparison, this analysis focused on funds with assets under management (AUM) exceeding Rs 1,500 crore. Within this group, the Nippon India Pharma Fund maintains the largest asset base, managing a corpus of approximately Rs 8,635.7 crore.
Short-Term vs Long-Term Dynamics
While the ICICI Pru P.H.D Fund holds the top position over the three-year horizon, leadership shifts when looking at shorter durations. For instance, the SBI Healthcare Opp Fund has demonstrated stronger results in recent months, leading its peers with an 8.9 percent return over one month and a 21.3 percent return over three months. Additionally, the SBI fund outperformed in the one-year category, delivering a 14.9 percent gain, whereas the ICICI Pru fund’s one-year performance was impacted by a benchmark that saw a negative return of 4.0 percent.
Risks of Sector-Specific Investing
Investors should keep in mind that sector-specific mutual funds operate differently than diversified equity funds. Because these funds concentrate their investments within the pharmaceutical, healthcare, and diagnostic industries, their performance is tied directly to the ups and downs of these specific businesses. If the healthcare sector faces regulatory changes, pricing pressure, or demand challenges, the fund's value can fluctuate more sharply than a broad-market fund. The divergence in performance between short-term and long-term periods emphasizes how sector fortunes can change quickly. Investors monitoring these funds should track both the long-term track record of the fund manager and the current performance trends within the healthcare sector to understand how these factors may influence future volatility and returns.